Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126349 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mara Carsote und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Insulin Resistance, Hypercalcemia, Pancreatitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania "Publish not Perish", Publication of this paper was supported by "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania through the institutional program "Publish no…, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania.
Abstract (Originalsprache)
We aimed to provide an in-depth analysis with respect to three turning points in pancreas involvement in primary hyperparathyroidism (PHP): hypercalcemia-induced pancreatitis (HCa-P), MEN1 (multiple endocrine neoplasia)-related neuroendocrine tumors (NETs), and insulin resistance (IR). This was a comprehensive review conducted via a PubMed search between January 2020 and January 2024. HCa-P (n = 9 studies, N = 1375) involved as a starting point parathyroid NETs (n = 7) or pancreatitis (n = 2, N = 167). Case report-focused analysis (N = 27) showed five cases of pregnancy PHP-HCa-P and three reports of parathyroid carcinoma (female/male ratio of 2/1, ages of 34 in women, men of 56). MEN1-NET studies (n = 7) included MEN1-related insulinomas (n = 2) or MEN1-associated PHP (n = 2) or analyses of genetic profile (n = 3), for a total of 877 MEN1 subjects. In MEN1 insulinomas (N = 77), the rate of associated PHP was 78%. Recurrence after parathyroidectomy (N = 585 with PHP) was higher after less-than-subtotal versus subtotal parathyroidectomy (68% versus 45%, p < 0.001); re-do surgery was 26% depending on surgery for pancreatic NETs (found in 82% of PHP patients). MEN1 pathogenic variants in exon 10 represented an independent risk factor for PHP recurrence. A single pediatric study in MEN1 (N = 80) revealed the following: a PHP rate of 80% and pancreatic NET rate of 35% and 35 underlying germline MEN1 pathogenic variants (and 3/35 of them were newly detected). The co-occurrence of genetic anomalies included the following: CDC73 gene variant, glucokinase regulatory protein gene pathogenic variant (c.151C>T, p.Arg51*), and CAH-X syndrome. IR/metabolic feature-focused analysis identified (n = 10, N = 1010) a heterogeneous spectrum: approximately one-third of adults might have had prediabetes, almost half displayed some level of IR as reflected by HOMA-IR > 2.6, and serum calcium was positively correlated with HOMA-IR. Vitamin D deficiency was associated with a higher rate of metabolic syndrome (n = 1). Normocalcemic and mildly symptomatic hyperparathyroidism (n = 6, N = 193) was associated with a higher fasting glucose and some improvement after parathyroidectomy. This multilayer pancreas/parathyroid analysis highlighted a complex panel of connections from pathogenic factors, including biochemical, molecular, genetic, and metabolic factors, to a clinical multidisciplinary panel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Department of Clinical Endocrinology V, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania.
- Department 4-Cardio-Thoracic Pathology, Thoracic Surgery II Discipline, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Thoracic Surgery Department, "Dr. Carol Davila" Central Military University Emergency Hospital, 010242 Bucharest, Romania.
- PhD Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Department of Clinical Biochemistry, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
ORCID-Profile: Mara Carsote, Claudiu Nistor, Mihai-Lucian Ciobica
Förderung
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania "Publish not Perish"
- Publication of this paper was supported by "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania through the institutional program "Publish no…
- “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Zitieren
APA
Carsote, M., Nistor, C., Gheorghe, A. M., Sima, O. C., Trandafir, A. I., Nistor, T. V. I., Sandulescu, B. A., & Ciobica, M. L. (2024). Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126349
Vancouver
Carsote M, Nistor C, Gheorghe AM, Sima OC, Trandafir AI, Nistor TVI, et al. Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126349
BibTeX
@article{Carsote2024,
author = {Carsote, Mara and Nistor, Claudiu and Gheorghe, Ana-Maria and Sima, Oana-Claudia and Trandafir, Alexandra-Ioana and Nistor, Tiberiu Vasile Ioan and Sandulescu, Bianca-Andreea and Ciobica, Mihai-Lucian},
title = {Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126349}
}
EUVIMED